TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04344275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -Scapular endurance test
Description: The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: -Scapular endurance test
Description: The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -Muscle strength test
Description: Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: -Muscle strength test
Description: Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
Study: NCT03229109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophon dehydration body monitor
Description: Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophon dehydration body monitor
Description: Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophon dehydration body monitor
Description: Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrophon dehydration body monitor
Description: Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
Study: NCT03719742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponsor Test Products
Description: Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
Study: NCT00725049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant (Nanotite)
Description: Root form titanium dental implant
Study: NCT02551263

Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
Study: NCT02038335

Intervention type: DRUG
Intervention: DMPA
Description: Depot medroxyprogesterone acetate

Intervention type: DRUG
Intervention: NET-EN
Description: Norethisterone enantate

Intervention type: DRUG
Intervention: MPA/E2
Description: Medroxyprogesterone acetate and estradiol cypionate

Intervention type: DEVICE
Intervention: LNG-I
Description: Levonorgestrel subdermal implant

Intervention type: DEVICE
Intervention: ENG-I
Description: Etonogestrel subdermal implant

Intervention type: DEVICE
Intervention: Cu-IUD
Description: Copper IUD
Study: NCT00448344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-supported
Description: Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Telephone counseling
Description: Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
Study: NCT01335620

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: 400 mg twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir
Description: 245 mg once daily
Study: NCT00410150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium-oxygen-driven albuterol nebulizer
Description: Subjects will be treated with continuous albuterol nebs with Heliox
Study: NCT01335620

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine
Description: 200mg once daily
Study: NCT02467543

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% Ethanol
Description: Unmedicated 20% Ethanol
Study: NCT02510001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
Study: NCT00410150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Subjects will be treated with continuous albuterol nebs in oxygen
Study: NCT02510001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
Study: NCT04321044

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation
Description: We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
Study: NCT02511886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen Placarbil
Description: Arbaclofen Placarbil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched tablets
Study: NCT01301313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intensified inotropic treatment
Description: Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
Study: NCT00730808

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PreOP Booster (food for special medical purposes)
Description: 3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster (food for special medical purposes)
Description: 3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
Study: NCT03307356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Transplant of a uterus from a donor, deceased or living
Study: NCT01615614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
Study: NCT02467543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viburnum opulus 3X
Description: Viburnum opulus 3X in a vehicle of 20% ethanol.
Study: NCT04099589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Gemcitabine/Cisplatin plus Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Gemcitabine/Cisplatin plus Toripalimab
Study: NCT00981695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
Study: NCT02696980

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Positive Expiratory Pressure
Description: Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure
Description: Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
Study: NCT01362894

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A contact lens
Description: Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A contact lens
Description: Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
Study: NCT02780284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: 150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
Study: NCT03529968

Intervention type: PROCEDURE
Intervention: esophagectomy
Description: Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy

Intervention type: PROCEDURE
Intervention: esophagectomy
Description: Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
Study: NCT03982680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2 on d1 and d15 q4W\*4cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- fluorine pyrimidine
Description: 400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
Study: NCT05314335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology socks+walking
Description: Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)

Intervention type: OTHER
Group type: OTHER
Intervention: Just walking
Description: Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
Study: NCT00031759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablative or excisional therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative or excisional therapy
Study: NCT04190901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Black Male Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Black Female Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated White Male Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated White Female Physician
Description: Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
Study: NCT02696980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure
Description: Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
Study: NCT00961727

Intervention type: OTHER
Intervention: Bedside Paediatric Early Warning System (Bedside PEWS)
Description: The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
Study: NCT04167449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HRG80 Hydroponic Red Ginseng
Description: Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional White Ginseng
Description: Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo capsule containing rice flour
Study: NCT04366011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capnometry Assisted Respiratory Training (CART)
Description: CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
Study: NCT01048710

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT03301207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg
Description: Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
Study: NCT04522167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB203 (Proposed aflibercept biosimilar)
Description: Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea® (Aflibercept)
Description: Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Study: NCT01107314

Intervention type: OTHER
Intervention: Phlebotomy
Description: Blood draws (total 48 cc blood)
Study: NCT01409876

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: interstitial image- guided PDR/HDR brachytherapy
Study: NCT01641601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient transcervical Foley balloon
Description: A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
Study: NCT00863499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short Acting Methylphenidate
Description: Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Acting Methylphenidate
Description: Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
Study: NCT03629522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8Mg/4mL Injection
Description: investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8Mg/4mL Injection
Description: investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
Study: NCT03053570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Description: use Cryoballoon to isolation the Pulmonary Vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Description: use Cryoballoon to isolation the Pulmonary Vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy(Contact Force)
Description: use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy(Contact Force)
Description: use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
Study: NCT01691157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence based exercise protocol
Description: An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy without exercise
Description: Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
Study: NCT00785980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine Sulfate Capsules 324 mg
Description: A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.